Advanced search
Publication Cover
Ocular Immunology and Inflammation Volume 29, 2021 - Issue 3
Submit an article Journal homepage
205
Views
4
CrossRef citations to date
0
Altmetric
Letter to the Editor

Primary Intraocular Methotrexate-related Lymphoproliferative Disorder in a Patient with Rheumatoid Arthritis Undergoing Long-term Methotrexate Therapy

Kumiko SoneDepartment of Ophthalmology, Tokyo Medical University, Tokyo, Japan
, MD,
Yoshihiko UsuiDepartment of Ophthalmology, Tokyo Medical University, Tokyo, JapanCorrespondence[email protected]
, MD, PhD,
Keiko FujiiDepartment of Ophthalmology, Tokyo Medical University, Tokyo, Japan
, MD &
Hiroshi GotoDepartment of Ophthalmology, Tokyo Medical University, Tokyo, Japan
, MD, PhD
Pages 456-459 | Received 15 Apr 2019, Accepted 12 Sep 2019, Published online: 28 Oct 2019

REFERENCES

  • Frenkel S, Hendler K, Siegal T, Shalom E, Pe’er J. Intravitreal methotrexate for treating vitreoretinal lymphoma:10 years of experience. Br J Ophthalmol. 2008;92(3):383–388. doi:10.1136/bjo.2007.127928.
  • Kaneko Y. Methotrexate-associated lymphoproliferative disorder. Nihon Rinsho Meneki Gakkai Kaishi. 2017;40(3):174–178. doi:10.2177/jsci.40.174.
  • Gaulard P, Swerdlow S, Harris N, Jaffe E, Sundstrom C. Other iatrogenic immunodeficiency-associated lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, et al., eds. World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008:350–351.
  • Huwait H, Wang B, Shustik C, Michel RP. Composite cutaneous lymphoma in a patient with rheumatoid arthritis treated with methotrexate. Am J Dermatopathol. 2010;32:65–70. doi:10.1097/DAD.0b013e3181af7dee.
  • Raparia K, Chang CC, Chevez-Barrios P. Intraocular lymphoma: diagnostic approach and immunophenotypic findings in vitrectomy specimens. Arch Pathol Lab Med. 2009;133(8):1233–1237. doi:10.1043/1543-2165-133.8.1233.
  • Salloum E, Cooper DL, Howe G, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol. 1996;14:1943–1949. doi:10.1200/JCO.1996.14.6.1943.
  • Fukushima M, Katayama Y, Yokose N, et al. Primary central nervous system malignant lymphoma in a patient with rheumatoid arthritis receiving low-dose methotrexate treatment. Br J Neurosurgery. 2013;27:824–826. doi: 10.3109/02688697.2013.798857
  • Kameda H, Fujii T, Nakajima A, Koike R, Sagawa A, Kanbe K. Japan college of rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis. Mod Rheumatol. 2019;29(1):31–40. doi:10.1080/14397595.2018.1472358.
  • Kashiwazaki S, Ichikawa Y, Sugawara S, et al. Determination of the clinical optimal dose of L-377(methotrexate capsule) for the treatment of rheumatoid arthritis. Jpn J Inflammat. 1996;16:437–458.
  • Ellman MH, Hurwitz H, Thomas C, Kozloff M Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate. J Rheumatoid. 1991;18:1741–1743.
  • Inui Y, Matsuoka H, Yakushijin K, et al. Methotrexate-associated lymphoproliferative disorders: management by watchful waiting and observation of early lymphocyte recovery after methotrexate withdrawal. Leuk Lymphoma. 2016;56:3045–3051. doi:10.3109/10428194.2015.1022769.
  • Hoshida Y, Xu JX, Fujita S, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol. 2007;34:322–331.
  • Kimura K, Usui Y, Goto H. Clinical features and diagnostic significance of the intraocular fluid of 217 patients with intraocular lymphoma. Jpn J Ophthalmol. 2012;56(4):383–389. doi:10.1007/s10384-012-0150-7.
  • Yamakawa N, Fujimoto M, Kawabata D, et al. A clinical pathological, pathological, and genetic characterization of methotrexate-associated lymphoproliferative disorders. J Rheumatol. 2014;41:293–299. doi:10.3899/jrheum.130270.
  • Grywalska E, Rolinski J. Epstein-Barr virus-associated lymphomas. Semin Oncol. 2015;42:291–303. doi:10.1053/j.seminoncol.2014.12.030.
  • Ichikawa A, Arakawa F, Kiyasu J, et al. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol. 2013;91:20–28. doi:10.1111/ejh.12116.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.